Tanzina Haque
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Tanzina Haque has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
Dorothy H. Crawford
3 shared publicationsClare Taylor
2 shared publicationsParvez Murad
2 shared publicationsPeter L. Amlot
2 shared publicationsAndrew K. Burroughs
Department of Immunology, Renal, Liver and Bone Marrow Transplant Centres, Royal Free Hospital School of Medicine , Hampstead, London
1 shared publicationAngela Iley
1 shared publication
Latest Publications
- 1 August 2002
- Published by Elsevier in The Lancet
- Vol. 360 (9331) , 436-442
Treatment of Epstein-Barr-virus-positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells
- 1 August 2002
- Published by Elsevier in The Lancet
- Vol. 360 (9331) , 436-442
Treatment of Epstein-Barr-virus-positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells
- 1 October 2001
- Published by Wolters Kluwer Health in Transplantation
- Vol. 72 (8) , 1399-1402
COMPLETE REGRESSION OF POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE USING PARTIALLY HLA-MATCHED EPSTEIN BARR VIRUS-SPECIFIC CYTOTOXIC T CELLS1
Adoptive immunotherapy with autologous and donor-derived cytotoxic T lymphocytes (CTL) has recently been used to treat Epstein Barr virus (EBV)-positive posttransplant lymphoproliferative disease (PTLD). We report complete regression of EBV-positive PTLD in an 18-month-old small bowel and liver transplant recipient after one infusion of partially human leukocyte antigen (HLA)-matched EBV-specific CTL grown ex vivo from an EBV seropositive unrelated blood donor. No infusion-related toxicity or evidence of graft-versus-host disease was observed. The tumor showed signs of regression within 1 week and EBV load in peripheral blood dropped to undetectable levels. Limiting dilution analyses (LDA) detected no EBV-specific CTL precursor (CTLp) cells before the infusion, and high numbers of CTLp at 4 hr and 24 hr post-CTL infusion. There was a reversal of the CD4/8 ratio in peripheral blood and an increase in HLA-DR positive CD8 cells. The patient has been in complete remission for 24 months. If this success is repeated in more PTLD patients, then stored CTL could be used for antiviral and antitumor therapies in immunocompromised patients.
- 1 October 2001
- Published by Wolters Kluwer Health in Transplantation
- Vol. 72 (8) , 1399-1402
COMPLETE REGRESSION OF POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE USING PARTIALLY HLA-MATCHED EPSTEIN BARR VIRUS-SPECIFIC CYTOTOXIC T CELLS1
Adoptive immunotherapy with autologous and donor-derived cytotoxic T lymphocytes (CTL) has recently been used to treat Epstein Barr virus (EBV)-positive posttransplant lymphoproliferative disease (PTLD). We report complete regression of EBV-positive PTLD in an 18-month-old small bowel and liver transplant recipient after one infusion of partially human leukocyte antigen (HLA)-matched EBV-specific CTL grown ex vivo from an EBV seropositive unrelated blood donor. No infusion-related toxicity or evidence of graft-versus-host disease was observed. The tumor showed signs of regression within 1 week and EBV load in peripheral blood dropped to undetectable levels. Limiting dilution analyses (LDA) detected no EBV-specific CTL precursor (CTLp) cells before the infusion, and high numbers of CTLp at 4 hr and 24 hr post-CTL infusion. There was a reversal of the CD4/8 ratio in peripheral blood and an increase in HLA-DR positive CD8 cells. The patient has been in complete remission for 24 months. If this success is repeated in more PTLD patients, then stored CTL could be used for antiviral and antitumor therapies in immunocompromised patients.
- Open Access
- 1 August 1999
- Published by Wiley in British Journal of Haematology
- Vol. 106 (2) , 309-316
THE ROLE OF ADOPTIVE IMMUNOTHERAPY IN THE PREVENTION AND TREATMENT OF LYMPHOPROLIFERATIVE DISEASE FOLLOWING TRANSPLANTATION
- 1 August 1999
- Published by Wiley in British Journal of Haematology
- Vol. 106 (2) , 309-316
Open AccessTHE ROLE OF ADOPTIVE IMMUNOTHERAPY IN THE PREVENTION AND TREATMENT OF LYMPHOPROLIFERATIVE DISEASE FOLLOWING TRANSPLANTATION
- Open Access
- 15 June 1998
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 160 (12) , 6204-6209
Reconstitution of EBV-Specific T Cell Immunity in Solid Organ Transplant Recipients
EBV-specific autologous CTL were grown in vitro from three adults (two liver transplant recipients and one patient on hemodialysis awaiting kidney retransplant). All CTL lines were TCR αβ, CD8 positive cells, EBV specific, and MHC class I restricted. The CTL lines were expanded in vitro and infused in three escalating doses (5 × 107, 1 × 108, and 2 × 108) at monthly intervals. Weekly blood samples were collected following each infusion. EBV-specific CTL precursor cells in peripheral blood were quantitated by limiting dilution analysis, and their effect on EBV load in vivo was assessed by semiquantitative PCR. In all three patients, the numbers of CTL precursor cells increased during the weeks following the infusions and were highest after the third infusion. This level gradually declined but remained above the preinfusion levels for up to 3 mo. EBV genome copy number, on the other hand, dropped following the first infusion and became undetectable thereafter. The EBV DNA level remained lower than the pretransplant level in all patients for up to 3 mo after the last infusion. Our study shows that it is feasible to generate and expand EBV-specific CTL from pretransplant blood samples of solid organ transplant recipients, that these CTL can be stored and infused posttransplant, and that they remain cytotoxic and EBV specific in vivo. The aim of this study is to use these CTL for prevention and treatment of lymphoproliferative disease in solid organ transplant recipients.
- 15 June 1998
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 160 (12) , 6204-6209
Open AccessReconstitution of EBV-Specific T Cell Immunity in Solid Organ Transplant Recipients
EBV-specific autologous CTL were grown in vitro from three adults (two liver transplant recipients and one patient on hemodialysis awaiting kidney retransplant). All CTL lines were TCR αβ, CD8 positive cells, EBV specific, and MHC class I restricted. The CTL lines were expanded in vitro and infused in three escalating doses (5 × 107, 1 × 108, and 2 × 108) at monthly intervals. Weekly blood samples were collected following each infusion. EBV-specific CTL precursor cells in peripheral blood were quantitated by limiting dilution analysis, and their effect on EBV load in vivo was assessed by semiquantitative PCR. In all three patients, the numbers of CTL precursor cells increased during the weeks following the infusions and were highest after the third infusion. This level gradually declined but remained above the preinfusion levels for up to 3 mo. EBV genome copy number, on the other hand, dropped following the first infusion and became undetectable thereafter. The EBV DNA level remained lower than the pretransplant level in all patients for up to 3 mo after the last infusion. Our study shows that it is feasible to generate and expand EBV-specific CTL from pretransplant blood samples of solid organ transplant recipients, that these CTL can be stored and infused posttransplant, and that they remain cytotoxic and EBV specific in vivo. The aim of this study is to use these CTL for prevention and treatment of lymphoproliferative disease in solid organ transplant recipients.
- 1 December 1997
- Published by Microbiology Society in Journal of General Virology
- Vol. 78 (12) , 3357-3360
PCR amplification is more sensitive than tissue culture methods for Epstein-Barr virus detection in clinical material.
In this study we have compared the use of PCR and conventional tissue culture methods to detect Epstein-Barr virus (EBV) in peripheral blood mononuclear cells and throat wash samples. The study population included 29 healthy adult and 20 immunocompromised EBV-seropositive donors. The results show significantly higher EBV detection rates by PCR than the tissue culture methods in throat wash samples from both donor groups (P < 0.01 in healthy donors and P < 0.009 in the immunocompromised donors) and in peripheral blood from the immunocompromised but not from the healthy donors (P < 0.008). Furthermore, when EBV DNA detection rates in throat wash cell pellet and supernatant fluid were compared, a higher positive result was obtained with the cell pellets which reached statistical significance in the immunocompromised group (P < 0.02). No correlation was found between positivity in throat wash and peripheral blood from the same donors.
- 1 December 1997
- Published by Microbiology Society in Journal of General Virology
- Vol. 78 (12) , 3357-3360
PCR amplification is more sensitive than tissue culture methods for Epstein-Barr virus detection in clinical material.
In this study we have compared the use of PCR and conventional tissue culture methods to detect Epstein-Barr virus (EBV) in peripheral blood mononuclear cells and throat wash samples. The study population included 29 healthy adult and 20 immunocompromised EBV-seropositive donors. The results show significantly higher EBV detection rates by PCR than the tissue culture methods in throat wash samples from both donor groups (P < 0.01 in healthy donors and P < 0.009 in the immunocompromised donors) and in peripheral blood from the immunocompromised but not from the healthy donors (P < 0.008). Furthermore, when EBV DNA detection rates in throat wash cell pellet and supernatant fluid were compared, a higher positive result was obtained with the cell pellets which reached statistical significance in the immunocompromised group (P < 0.02). No correlation was found between positivity in throat wash and peripheral blood from the same donors.